Regeneron (REGN) Receives a Buy from RBC Capital

RBC Capital analyst Brian Abrahams maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,189.00. The company’s shares closed yesterday at $938.48.

Abrahams covers the Healthcare sector, focusing on stocks such as Regeneron, Gilead Sciences, and Vertex Pharmaceuticals. According to TipRanks, Abrahams has an average return of 9.4% and a 50.00% success rate on recommended stocks.

In addition to RBC Capital, Regeneron also received a Buy from Truist Financial’s Robyn Karnauskas in a report issued on March 26. However, on March 25, Bank of America Securities maintained a Sell rating on Regeneron (NASDAQ: REGN).

Based on Regeneron’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $3.43 billion and a net profit of $1.16 billion. In comparison, last year the company earned a revenue of $3.41 billion and had a net profit of $1.2 billion

Based on the recent corporate insider activity of 100 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of REGN in relation to earlier this year. Most recently, in February 2024, George Sing, a Director at REGN sold 1,000.00 shares for a total of $992,500.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Regeneron (REGN) Company Description:

Founded in 1988, Regeneron Pharmaceuticals, Inc. is a New York-based biotechnology company, which discovers, develops, manufactures, and commercializes medicines for the treatment of various medical conditions. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP.